BMS, J&J Japan Units Vie For Hepatitis C Drugs With Fewer Side Effects
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb and Johnson & Johnson units are vying for Japan's market for milder versions of hepatitis C drugs for nearly 2 million people with the disease.